Ke Geng Bio

A member of the firm’s Policy Committee and managing partner of the Beijing office, Ke advises clients across numerous industries in connection with financings for Chinese companies, mergers and acquisitions, and other corporate matters. Ke has been named one of China’s 100 Elite Lawyers by China Business Law Journal for the past two years. Prior to entering the legal profession, he earned a B.S. degree in Biology from Peking University and a Ph.D. in Biochemistry from New York University. Ke led the O’Melveny team for RemeGen’s Hong Kong IPO, which was recognized as Deal of the Year by China Business Law Journal and Megatrend Deal of the Year – Healthcare by FinanceAsia. Ke is highly rated for China capital markets by Chambers Asia Pacific, Chambers Greater China Region and Chambers Global.